Details of the Drug

General Information of Drug (ID: DM8MJ3F)

Drug Name
PB1046
Synonyms Pemziviptadil; PB1046 Vasomera; PB-1120 Vasomera
Indication
Disease Entry ICD 11 Status REF
Heart failure BD10-BD13 Phase 2 [1]
Pulmonary arterial hypertension BB01.0 Phase 2 [2]
Cardiomyopathy BC43 Phase 1 [3]
Duchenne dystrophy 8C70 Phase 1 [1]
Hypertension BA00-BA04 Phase 1 [4]
Drug Type
Recombinant protein
Cross-matching ID
TTD ID
D0G9JQ
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Helodermin-preferring VIP receptor (VIPR2) TT4O5P0 VIPR2_HUMAN Agonist [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Heart failure
ICD Disease Classification BD10-BD13
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Helodermin-preferring VIP receptor (VIPR2) DTT VIPR2 1.54E-01 -0.08 -0.4
Helodermin-preferring VIP receptor (VIPR2) DTT VIPR2 6.31E-01 6.73E-03 0.03
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT03795428) Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004 (VIP Extend). U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of PhaseBio.
5 Clinical pipeline report, company report or official report of PhaseBio Pharmaceuticals.